Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
152 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01084252 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 351 | SanofiINDUSTRY | 17 | Nov 1, 2024 | clinicaltrials |
| NCT06648902 | Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue | completed | Phase 1 / Phase 2 | 60 | Kidney Cancer Research BureauOTHER | 3 | Oct 18, 2024 |
| NCT03875079 | A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 7 | Oct 3, 2024 | clinicaltrials |
| NCT06175338 | Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis | active not recruiting | Phase 1 | 208 | Mabscale, LLCINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03284723 | PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors | terminated | Phase 1 | 95 | PfizerINDUSTRY | 6 | Sep 3, 2024 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05009719 | Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy | completed | Phase 1 / Phase 2 | 50 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03292263 | ASCT With Nivolumab in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT04540705 | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread(PIVOT IO 011) | completed | Phase 1 | 30 | Bristol-Myers SquibbINDUSTRY | 8 | Feb 28, 2024 | clinicaltrials |
| NCT03006926 | A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 104 | Eisai Co., Ltd.INDUSTRY | 7 | Dec 13, 2023 | clinicaltrials |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 128 | H3 Biomedicine Inc.INDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT01133990 | FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 5 | Eisai Inc.INDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT03330405 | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 223 | PfizerINDUSTRY | 9 | Oct 13, 2023 | clinicaltrials |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) | completed | Phase 1 / Phase 2 | 113 | Ionis Pharmaceuticals, Inc.INDUSTRY | 6 | Oct 6, 2023 | clinicaltrials |
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT05782959 | Phase 1 Study of BCD-245 in Subjects With Neuroblastoma | unknown | Phase 1 | 24 | BiocadINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00481936 | Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin | terminated | Phase 1 | 15 | Sesen Bio, Inc.INDUSTRY | 2 | Mar 23, 2023 | clinicaltrials |
| NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT03467256 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | unknown | Phase 1 / Phase 2 | 18 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT04499573 | Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL | active not recruiting | Phase 1 / Phase 2 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 109 | Kartos Therapeutics, Inc.INDUSTRY | 8 | Mar 21, 2022 | clinicaltrials |
| NCT03551782 | A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 33 | Janssen Research & Development, LLCINDUSTRY | 7 | Feb 25, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT03006029 | Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms(TAB08) | completed | Phase 1 | 12 | Theramab LLCINDUSTRY | 1 | Oct 6, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03077607 | A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors | completed | Phase 1 | 36 | PfizerINDUSTRY | 4 | Jun 30, 2021 | clinicaltrials |
| NCT03259529 | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL(BeGeRN) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT01075048 | ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 131 | Daiichi SankyoINDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01323530 | A Confirmation Study of Eribulin in Combination With Capecitabine | completed | Phase 1 / Phase 2 | 76 | Eisai LimitedINDUSTRY | 3 | Jan 11, 2021 | clinicaltrials |
| NCT00456833 | Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy | completed | Phase 1 | 248 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 21, 2020 | clinicaltrials |
| NCT02799147 | GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | completed | Phase 1 / Phase 2 | 27 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 6 | Nov 20, 2020 | clinicaltrials |
| NCT03343652 | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma(NB001) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT02608034 | A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | completed | Phase 1 | 32 | Genentech, Inc.INDUSTRY | 4 | Feb 12, 2020 | clinicaltrials |
| NCT03343665 | Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma(Nivo40) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00343564 | A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 68 | CytokineticsINDUSTRY | 2 | Jan 13, 2020 | clinicaltrials |
| NCT04180774 | Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer | completed | Phase 1 / Phase 2 | 80 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT01883518 | Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma(ADCVCTAST) | unknown | Phase 1 / Phase 2 | 48 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT04071184 | Study of Alofanib in Patients With Metastatic Gastric Cancer | unknown | Phase 1 | 50 | Russian Pharmaceutical TechnologiesINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials